Navigation Links
Targeted agent shows promise for chronic lymphoid leukemia

COLUMBUS, Ohio Researchers at the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) have identified an experimental agent that targets chronic lymphocytic leukemia and perhaps other proliferative disorders of lymphocytes.

Their study shows that the small-molecule inhibitor CAL-101 directly promotes cell death by apoptosis in chronic lymphocytic leukemia (CLL) cells and disrupts several external survival pathways needed for CLL cell viability and proliferation.

The agent blocks a molecule called PI3K-delta, an isomer of the PI3K (phosphatidylinositol-3 kinase) pathway, which is activated mainly in blood-forming, or hematopoietic, cells.

The research used cells from patient tumors and was posted recently in the journal Blood.

"Overall, our findings provide a rationale for the development of CAL-101 as the first in a new class of targeted therapies for CLL," says principal investigator Amy J. Johnson, assistant professor of hematology and medicinal chemistry, and a CLL researcher in the OSUCCC-James.

"A PI3K inhibitor hasn't been developed yet because this pathway is required for many essential cellular functions, but the identification of PI3K-delta, which is hematopoietic-selective, unlocks a potential new therapy for B-cell malignancies," Johnson says.

CLL is the most common from of adult leukemia in the United States, with about 15,000 new cases and 4,500 deaths annually. An estimated 100,760 people in the United States are living with or are in remission from CLL.

People with the asymptomatic phase of CLL can live many years, even without treatment. But once the disease progresses to its symptomatic phase, treatment is required. This is usually a chemotherapy-based regimen that often induces remission. But current therapies are not curative and nearly all patients relapse.

The PI3K pathway is essential for survival of cells generally. This made it an unsuitable target for small molecule inhibitors until recently when research showed that PI3K-delta expression occurs mainly in hematopoietic cell types. Preclinical studies suggest that blocking this molecule may kill B cells with little toxicity to other hematopoietic cells.

The present study, which used CLL cells from patients, found the following:

  • CLL cells show high PI3K pathway activity and PI3K-delta expression;
  • CAL-101 preferentially kills CLL cells compared to normal B-cells;
  • CAL-101 selectively inhibits PI3K-delta and directly promotes apoptosis in primary CLL cells, and it disrupts multiple external survival pathways;
  • CAL-101 cell killing is caspase dependent and not diminished by the presence of stromal cells;
  • CAL-101 does not kill normal T-cells or NK cells or reduce antibody-dependent cellular cytotoxicity, but it does lower production of inflammatory and anti-apoptotic cytokines by activated T-cells.


Contact: Darrell E. Ward
Ohio State University Medical Center

Related medicine news :

1. Targeted strategies needed to find, prevent and treat breast cancer among Mexican-origin women
2. In Early Trial, Targeted Therapy Fights Advanced Melanoma
3. New targeted therapy for advanced melanoma associated with 80 percent response rate
4. Targeted drug leads to regression of metastatic melanoma with mutated BRAF gene
5. NYU Langone offers vascular-targeted photodynamic therapy for localized prostate cancer
6. Radiation device allows for targeted breast radiation to control cancer
7. Surveillance colonoscopy should be targeted to high-risk patients
8. Combined BRAF-targeted and immunotherapy shows promise for melanoma treatment
9. Experimental targeted therapy shows early promise against medulloblastomas
10. Targeted Therapy Shows Promise Against Deadly Brain Cancer
11. Targeted Radiation for Early Breast Cancer a Good Option: Study
Post Your Comments:
(Date:11/30/2015)... Madeira Beach, FL (PRWEB) , ... November 30, ... ... issue of Consumer Reports magazine, quoted Michael Hansen, Ph.D., a senior scientist at ... exposure, and even more so for a child’s exposure limits. , The original ...
(Date:11/30/2015)... ... November 30, 2015 , ... Medicalis, a ... Radiology Society of North America (RSNA) annual meeting, being held November 29 – ... 2014. Throughout 2015, the company has completed installations for Integrated Delivery Network ...
(Date:11/30/2015)... ... ... It’s inevitable that everyone will experience death in his or her lifetime. ... lives among us. It is your perspective, however, that determines how you view death ... T Sky understands that she may see death more frequently than most. As she ...
(Date:11/30/2015)... ... ... The successful filing of an Investigational New Drug application (IND) is a ... key industry segment, Regis Technologies has decided to sponsor and participate in an XTalks-hosted ... , Federal law does not allow new drugs to cross state lines until it ...
(Date:11/30/2015)... ... ... Scott Newman MD, FACS of New York’s Advanced Plastic ... the New York City area to utilize the new, non-invasive SculpSure™ Laser System ... for fat loss in the abdomen, flanks, and other areas that is completely ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... 30, 2015  PTS Diagnostics, the U.S.-based manufacturer of ... analyzers, A1CNow ® systems, and PTS Detect™ cotinine ... patents that will propel the company into the mHealth ... Europe . The technology is a system ... on smartphones and tablets, and uses test strip technology ...
(Date:11/30/2015)... NASHUA, N.H. , Nov. 30, 2015 /PRNewswire/ ... today that it will feature its latest solutions ... the early identification of cancer at the Radiological ... in Chicago from November ... showcase recent product advances including iReveal®, an automated ...
(Date:11/30/2015)... -- Hanger, Inc. (NYSE: HGR ) (the "Company") today ... its previously announced consent solicitation (as amended and restated, ... amount 7⅛% Senior Notes due 2018 (the "Notes") to ... pursuant to the Consent Solicitation, (ii) the proposed increased ... date of the Consent Solicitation.    ...
Breaking Medicine Technology: